The biomanufacturing industry is currently undergoing a revolution in how it produces biopharmaceutical products. The driving force behind this paradigm shift is known as...
Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...
Sponsor: TriLink BiotechnologiesIn this GEN webinar, sponsored by TriLink Biotechnologies, we will hear about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather that the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.
Sponsor: SolentimIn this GEN webinar, we will discuss how the VIPS™ (Verified in-situ Plate Seeding) system, in combination with the SAL Scientific single-cell cloning supplements, offer customers a high-efficiency solution which ensures plates are populated with high numbers of healthy single cells that grow into resultant colonies for screening, expansion and further selection to master cell banks.
Sponsor: RedShiftBioIn this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.
Sponsored by: 3DS Dassault Systemes REGISTER NOW Broadcast Date: February 5, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates (ADCs) were initially developed to provide a selective targeting...
Sponsor: TecanJoin us for Episode 4 of GEN Live, sponsored by Tecan. In this live zoom event we discuss the state of vaccine development for COVID-19. We evaluate the front-runners, explore the potential of RNA vaccines, ponder the challenges of manufacturing, and tackle questions about herd immunity.
Sponsor: RedShiftBioIn this GEN webinar, we will review pressure-assisted protein refolding and pressure perturbation coupled with MMS to study protein stability in biopharmaceutical formulations.
Sponsor: CarterraIn this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.